Network-based hub biomarker discovery for glaucoma

Xueli Zhang, Shuo Ma, Xianwen Shang, Xiayin Zhang, Lingcong Kong, Ha Jason, Yu Chuan Huang, Zhuoting Zhu, Shunming Liu, Katerina Kiburg, Danli Shi, Yueye Wang, Yining Bao, Hao Lai, Wei Wang, Yijun Hu, Ke Zhao, Guang Hu, Huiying Liang, Honghua Yu, Lei Zhang, Mingguang HebioRxiv 2022 · DOI

TL;DR

This study leverages network medicine to identify key biomarkers and drug targets for glaucoma, a leading cause of irreversible blindness. By analyzing complex biological interaction networks, the researchers pinpointed crucial molecules and pathways that could pave the way for earlier diagnosis, improved treatment, and better prognosis for glaucoma patients.

What Problem Does This Paper Address?

Glaucoma is a silent thief of sight, often progressing without noticeable symptoms until significant, irreversible vision loss has occurred. This makes early detection and effective treatment incredibly challenging. Current diagnostic and therapeutic strategies are far from optimal, highlighting a critical need for reliable biomarkers that can facilitate early diagnosis, identify individuals at high risk of progression, and guide treatment decisions. The complex, multifactorial nature of glaucoma suggests that understanding the intricate relationships between genes, biomolecules, and disease pathways is essential, a task well-suited for network medicine approaches.

Methods

The researchers employed a network medicine approach, constructing two primary networks:

  1. Human Disease-Biomarker Interaction Network (HDBIN): This network integrates information on human diseases and their associated biomarkers.
  2. Human Disease-Target-Drug Interaction Network (HDTDIN): This network connects human diseases with their corresponding drug targets and drugs.

They utilized a "greedy search algorithm" (specifically, the jActiveModules plugin in Cytoscape) to identify "hub networks" – densely interconnected subnetworks within the larger networks that are likely to be biologically significant. These hub networks were then analyzed for key biomarkers and drug targets. To validate their findings, the study incorporated various data sources, including:

  • Genomic data: Genome-Wide Association Studies (GWAS) were used to verify gene-level relationships.
  • Epidemiological data: The UK Biobank provided population-based data for validation.
  • Text-mining: Published literature was used to gather application information for biomarkers.
  • Gene expression data: Data from the GEO database was used to assess the diagnostic value of identified biomarkers.
  • Protein-protein interaction (PPI) networks: Data from the STRING database was used to explore relationships between identified biomarkers.

Datasets

The study utilized several publicly available databases:

  • Therapeutic Target Database (TTD): For biomarker-disease, drug-target, and target-disease interactions.
  • STRING database: For protein-protein interaction (PPI) information.
  • KEGG database: For pathway information.
  • Reactome database: For pathway information.
  • Gene Ontology database: For pathway information.
  • GWAS Catalog database: For disease-related GWAS data.
  • UK Biobank database: For epidemiological data.
  • GEO database: For gene expression data (specifically GSE2378, GPL8300 platform).

No new benchmarks were introduced; the study focused on integrating and analyzing existing data.

Key Insights and Ideas

  • Network medicine as a powerful lens for glaucoma: The study demonstrates that analyzing glaucoma through the lens of complex biological networks can reveal insights not easily discernible through traditional methods. It highlights the interconnectedness of diseases, biomarkers, and drug targets.
  • Hub biomarkers with multi-functional potential: The identified "hub" biomarkers are not just associated with diagnosis but also show potential for treatment and prognosis, reinforcing the idea that key molecules often play multifaceted roles in complex diseases.
  • Predicting novel diagnostic applications: The research identified BMP1 and TUBA1A as potential new diagnostic biomarkers for glaucoma, expanding the current diagnostic toolkit.
  • Uncovering critical pathways: The study identified key biological pathways (e.g., regulation of multicellular organismal process, signal transduction) associated with these hub biomarkers and targets, providing crucial context for their roles and potential therapeutic interventions.
  • Disease-disease associations: The network analysis revealed glaucoma-related "neighbor" diseases, offering a broader perspective on the systemic implications of glaucoma and potential shared underlying mechanisms.

Key Results

  • The study constructed a Human Disease-Biomarker Interaction Network (HDBIN) with 1480 nodes and 2512 edges, and a Glaucoma Hub Biomarker Network (GHBN) comprising 68 glaucoma-related diseases and 123 biomarkers.
  • Eleven glaucoma-closest diseases (GNND) were identified, with asthma, dry eye disease, and myocardial infarction showing significant relationships with glaucoma in UK Biobank data.
  • Ten hub biomarkers were identified, including GFAP, MMP9, TUBA1A, and BMP1, which demonstrated significant diagnostic effects in ROC curve analysis (AUCs ranging from 0.619 to 0.857).
  • Six hub drug targets for glaucoma were identified: ADRB3, REN, AKR1B1, CaC, ADR, and ROCK, with pathways like signal transduction and developmental process being enriched.

Limitations and Future Work

  • Need for experimental validation: The authors acknowledge that while their findings are robustly supported by multiple datasets, they require further experimental verification in clinical settings.
  • Broader network analysis: The study suggests that further exploration of multimorbidity networks associated with glaucoma could uncover additional underlying biomarkers and pathways.
  • Drug discovery platform: The identified pathways, particularly signal transduction, are proposed as important platforms for future glaucoma drug discovery.
  • Expanding biomarker utility: The study posits that BMP1 and TUBA1A, identified as potential diagnostic biomarkers, may also have future value in treatment and prognosis.

Summary updated

Abstract

ABSTRACT Glaucoma is an optic neuropathy, and the leading cause of irreversible blindness worldwide. However, the early detection of glaucoma remains challenging as chronic forms of glaucoma remain largely asymptomatic until considerable irreversible visual field deficits have ensued. Thus, biomarkers that facilitate early diagnosis and treatment for patients with a high risk of progression are critical. Network medicine approaches can be useful in identifying key relationships and important biomolecules for complex diseases. In this paper, we identified several hub biomarkers/drug targets for the diagnosis, treatment and prognosis for glaucoma and explored their associations for glaucoma based on human disease-biomarker and disease-target-drug networks. These results were verified by text-mining and genomic/epidemiology data. We also predicted the new application of BMP1 and MMP9 to diagnose glaucoma and confirm the theory of hub biomarkers with multiple clinical applications. Further, relevant pivotal pathways (regulation of the multicellular organismal process, regulation of localisation, and cytoplasmic vesicle for biomarkers; signal transduction and developmental process for targets) for these hub biomolecules were discovered, which may be foundations for future biomarker and drug target prediction for glaucoma. In conclusion, based on complex networks, hub biomolecules, essential pathways, and close diseases were identified for glaucoma in diagnosis, treatment and prognosis.
BibTeX
@misc{zhang2022network,
  author = {Xueli Zhang and Shuo Ma and Xianwen Shang and Xiayin Zhang and Lingcong Kong and Ha Jason and Yu Chuan Huang and Zhuoting Zhu and Shunming Liu and Katerina Kiburg and Danli Shi and Yueye Wang and Yining Bao and Hao Lai and Wei Wang and Yijun Hu and Ke Zhao and Guang Hu and Huiying Liang and Honghua Yu and Lei Zhang and Mingguang He},
  title = {{Network-based hub biomarker discovery for glaucoma}},
  year = {2022},
  doi = {10.1101/2022.10.09.511456},
  howpublished = {bioRxiv},
}
Figure